P. Kushner

发表

The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen

David A. Agard, Andrew K. Shiau, D. Agard, 1998, Cell.

p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

M. Erdos, E. Rosen, I. Goldberg, 2002, Cancer research.

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

C. Harmon, G. Greene, P. Kushner, 2018, Nature Communications.

Positive and negative modulation of Jun action by thyroid hormone receptor at a unique AP1 site

J. Baxter, P. Webb, P. Kushner, 1993, Molecular and cellular biology.

Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element.

P. Webb, P. Kushner, R. Uht, 1997, Endocrinology.

Estrogen receptor accessory proteins: effects on receptor-DNA interactions.

G. Greene, P. Kushner, C. Landel, 1995, Environmental health perspectives.

Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells.

P. Kushner, J. Schilling, A. Protter, 1987, The Journal of biological chemistry.

Estrogen receptor accessory proteins augment receptor-DNA interaction and DNA bending

G. Greene, A. Nardulli, P. Kushner, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.

J. Baxter, P. Webb, G. Greene, 1999, Molecular endocrinology.

ERβ Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus

J. Baxter, P. Webb, P. Kushner, 2003, Nuclear receptor.

Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.

M. Karin, P. Webb, P. Kushner, 2001, Molecular endocrinology.

Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities.

M. Stallcup, P. Kushner, Han Ma, 1998, Molecular endocrinology.

p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.

T. Curiel, J. McLachlan, P. Kushner, 2006, Molecular endocrinology.

The ER/AP1 Pathway: A Window on the Cell-Specific Estrogen-like Effects of Antiestrogens

P. Webb, P. Kushner, T. Scanlan, 1998 .

Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis.

J. Katzenellenbogen, K. Carlson, G. Greene, 1995, Biochemistry.

Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

P. Webb, P. Kushner, P. Nguyen, 2003, The Journal of biological chemistry.

Truncated forms of DNA-binding estrogen receptors in human breast cancer.

C. Benz, G. Scott, P. Kushner, 1991, The Journal of clinical investigation.

Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens.

J. Shine, J. Baxter, G. Greene, 1990, Molecular endocrinology.

High Expression in Mammalian Cells Without Amplification

J. Shine, J. Kushner, P. Gray, 1989, Bio/Technology.

Oestrogen receptor function at classical and alternative response elements.

D. Agard, P. Webb, G. Greene, 2000, Novartis Foundation symposium.

Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist.

R. Fletterick, J. Baxter, P. Webb, 2002, Endocrinology.

Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies.

R. Fletterick, J. Baxter, P. Kushner, 1998, Recent progress in hormone research.

Paradoxical production of target protein using antisense RNA expression vectors.

C. Benz, C. Hunt, J. Baxter, 1994, Gene.

The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins.

G. Greene, P. Kushner, C. Landel, 1994, Molecular endocrinology.

Restoration of estrogen-dependent progesterone receptor expression in a uterine myocyte cell line.

Y. Sadovsky, P. Kushner, J. Roberts, 1993, Endocrinology.

Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors.

R J Fletterick, J D Baxter, R. Fletterick, 1998, Science.

Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity*

B. Katzenellenbogen, S. Fuqua, S. Kato, 2001, The Journal of Biological Chemistry.

Eukaryotic regulatory elements lurking in plasmid DNA: the activator protein-1 site in pUC.

J. Baxter, P. Webb, P. Kushner, 1994, Molecular endocrinology.

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

J. Gustafsson, P. Webb, P. Kushner, 1997, Science.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF‐1 receptor tyrosine kinases, blocks the growth of HER2‐overexpressing human breast cancer cells

P. Kushner, L. Hodges, J. Youngren, 2008, Journal of cellular biochemistry.

The limits of the cellular capacity to mediate an estrogen response.

J. Baxter, P. Webb, G. Greene, 1992, Molecular endocrinology.

Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.

P. Webb, P. Kushner, R. Uht, 1995, Molecular endocrinology.

Design of thyroid hormone receptor antagonists from first principles

Thomas S. Scanlan, Patrick Goede, Grazia Chiellini, 2002, The Journal of Steroid Biochemistry and Molecular Biology.

Estrogen receptor pathways to AP-1

D. Agard, P. Webb, G. Greene, 2000, The Journal of Steroid Biochemistry and Molecular Biology.

The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

B. Katzenellenbogen, J. Gustafsson, P. Webb, 1999, Molecular endocrinology.

MUTATIONS OF THE HMa AND HMα LOCI AND THEIR BEARING ON THE CASSETTE MODEL OF MATING TYPE INTERCONVERSION IN YEAST

I. Herskowitz, P. Kushner, L. Blair, 1979 .

Role of direct interaction in BRCA1 inhibition of estrogen receptor activity

M. Erdos, E. Rosen, I. Goldberg, 2001, Oncogene.

Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression*

Chris Albanese, Paul Webb, P. Webb, 2002, The Journal of Biological Chemistry.

Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins

G. Coetzee, P. Webb, Shih-Ming Huang, 1999, Molecular and Cellular Biology.

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

M. Dowsett, C. Benz, G. Scott, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.

P. Kushner, M. Parker, F. L'horset, 1995, The EMBO journal.

Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein

Y. Sadovsky, J. Baxter, P. Webb, 1995, Molecular and cellular biology.

Cyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor α Activity

B. Katzenellenbogen, B. Weber, M. Lisanti, 2005 .

MOLECULAR AND STRUCTURAL BIOLOGY OF THYROID HORMONE RECEPTORS

R. Fletterick, J. Baxter, P. Webb, 1998, Clinical and experimental pharmacology & physiology. Supplement.

Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli.

J. Katzenellenbogen, K. Carlson, G. Greene, 1995, Molecular endocrinology.

Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expressed in Escherichia co/i

K. Carlson, G. Greene, P. Kushner, 1995 .

The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs).

J. Baxter, P. Webb, P. Kushner, 2000, Molecular endocrinology.

The nuclear hormone receptor gene superfamily.

J D Baxter, J. Baxter, P. Kushner, 1995, Annual review of medicine.

Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding.

D. Moore, P. Kushner, P. Pissios, 2000, Molecular cell.

Thyroid hormone alters in vitro DNA binding of monomers and dimers of thyroid hormone receptors.

J. Baxter, P. Kushner, B. West, 1992, Molecular endocrinology.

Structure and specificity of nuclear receptor-coactivator interactions.

R J Fletterick, J D Baxter, R. Fletterick, 1998, Genes & development.

Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity*

C. Turck, M. Stallcup, P. Kushner, 2001, The Journal of Biological Chemistry.

Screening and characterization of estrogenic activity from a hydroxystilbene library.

C. Benz, C. Hunt, P. Kushner, 1995, Chemistry & biology.

Enhancing Hormonal Therapy for Breast Cancer by Combination with a Well-Known Approved Pharmaceutical with Little Toxicity

P. Kushner, 2008 .

Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells

P. Kushner, C. Valentine, Cathleen D. Valentine, 2007, Breast Cancer Research and Treatment.

Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity

E. Zandi, M. Karin, J. Baxter, 1997, Molecular and cellular biology.

Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells

P. Kushner, C. Valentine, Cathleen D. Valentine, 2008, Breast Cancer Research and Treatment.

A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor

P. Webb, P. Kushner, C. Valentine, 2004, Nuclear receptor.

Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo *

P. Webb, P. Kushner, P. Nguyen, 2003, The Journal of Biological Chemistry.

Estrogen receptor activation function 1 works by binding p160 coactivator proteins.

B. Katzenellenbogen, P. Webb, D. Chen, 1998, Molecular endocrinology.

Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

J. Gustafsson, J. Baxter, P. Webb, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Control of yeast cell types by mobile genes: a test.

I. Herskowitz, P. Kushner, L. Blair, 1979, Proceedings of the National Academy of Sciences of the United States of America.

X-ray crystallographic and functional studies of thyroid hormone receptor 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997.

R. Fletterick, J. Baxter, P. Kushner, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

Chris Albanese, Paul Webb, P. Webb, 2002, The Journal of biological chemistry.

Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

C. Harmon, P. Klein, P. Kushner, 2022, Cancer Research.

Estrogen and Progesterone Receptor Analysis and Action in Breast Cancer

P. Gilna, G. Greene, P. Kushner, 1989 .

An Antiestrogen-responsive Estrogen Receptor-α Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen*

P. Webb, P. Kushner, T. Scanlan, 2000, The Journal of Biological Chemistry.

Coactivator Proteins of the 160-Kilodalton Nuclear Receptor Multiple Signal Input and Output Domains

G. Coetzee, P. Webb, Shih-Ming Huang, 1999 .

A Splice Variant of Estrogen Receptor β Missing Exon 3 Displays Altered Subnuclear Localization and Capacity for Transcriptional Activation.

P. Webb, P. Kushner, R. Handa, 2001, Endocrinology.

A plasmid that replicates in both mouse and E. coli cells.

H. Goodman, P. Kushner, B. Levinson, 1982, Journal of molecular and applied genetics.

OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors

C. Harmon, P. Klein, P. Kushner, 2020 .

Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer

C. Harmon, N. Lin, P. Klein, 2021 .

Characterization of human prorenin expressed in mammalian cells from cloned cDNA.

J. Fiddes, J. Shine, J. Baxter, 1986, Proceedings of the National Academy of Sciences of the United States of America.

A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation.

P. Webb, P. Kushner, R. Handa, 2001, Endocrinology.

Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

B. Katzenellenbogen, B. Weber, M. Lisanti, 2005, Cancer research.

Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist.

R. Fletterick, J. Baxter, P. Webb, 2002, Endocrinology.

Estrogen receptor action through target genes with classical and alternative response elements

P. Webb, P. Kushner, R. Uht, 2003 .